podophyllotoxin has been researched along with Endometrial Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, L; Du, M; Lv, Q | 1 |
| Chen, S; Lei, X; Tang, C; Xiong, YL; Xu, WJ; Zhao, KW; Zhou, Q | 1 |
2 other study(ies) available for podophyllotoxin and Endometrial Neoplasms
| Article | Year |
|---|---|
Picropodophyllin inhibits type I endometrial cancer cell proliferation via disruption of the PI3K/Akt pathway.
Topics: Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Phosphatidylinositol 3-Kinases; Phosphorylation; Podophyllotoxin; Prognosis; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Signal Transduction; Survivin | 2019 |
Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Californium; Carmustine; Combined Modality Therapy; Cytarabine; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Treatment Outcome | 2016 |